Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.

Frandsen TL, Abrahamsson J, Lausen B, Vettenranta K, Heyman M, Behrentz M, Castor A, Wehner PS, Frost BM, Andersen EW, Schmiegelow K.

Br J Haematol. 2011 Oct;155(2):244-7. doi: 10.1111/j.1365-2141.2011.08835.x. Epub 2011 Aug 18.

PMID:
21848519
3.

Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthøj S, Vettenranta K, Wesenberg F, Saarinen-Pihkala U; Nordic Society of Paediatric Haematology and Oncology (NOPHO).

J Pediatr Hematol Oncol. 2009 Jun;31(6):385-92. doi: 10.1097/MPH.0b013e3181a6e171.

PMID:
19648786
4.

Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.

Mahoney DH Jr, Camitta BM, Leventhal BG, Shuster JJ, Civin CJ, Ganick DJ, Lauer SJ, Steuber CP, Kamen BA.

Cancer. 1995 May 15;75(10):2623-31.

5.

Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.

Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE.

Blood. 1999 May 1;93(9):2817-23.

6.

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R; Nordic Society for Paediatric Haematology and Oncology.

Blood. 2009 Jun 11;113(24):6077-84. doi: 10.1182/blood-2008-11-187880. Epub 2009 Feb 17.

7.

Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.

Vang SI, Schmiegelow K, Frandsen T, Rosthøj S, Nersting J.

Cancer Chemother Pharmacol. 2015 May;75(5):1089-93. doi: 10.1007/s00280-015-2717-8. Epub 2015 Mar 19.

PMID:
25788208
8.

Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.

Levinsen M, Rosthøj S, Nygaard U, Heldrup J, Harila-Saari A, Jonsson OG, Bechensteen AG, Abrahamsson J, Lausen B, Frandsen TL, Weinshilboum RM, Schmiegelow K.

Cancer Chemother Pharmacol. 2015 Jan;75(1):59-66. doi: 10.1007/s00280-014-2613-7. Epub 2014 Oct 28.

9.

Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.

Levinsen M, Rotevatn EØ, Rosthøj S, Nersting J, Abrahamsson J, Appell ML, Bergan S, Bechensteen AG, Harila-Saari A, Heyman M, Jonsson OG, Maxild JB, Niemi M, Söderhäll S, Schmiegelow K; Nordic Society of Paediatric Haematology, Oncology.

Pediatr Blood Cancer. 2014 May;61(5):797-802. doi: 10.1002/pbc.24921. Epub 2014 Jan 3.

PMID:
24395436
11.

Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.

van Kooten Niekerk PB, Schmiegelow K, Schroeder H.

Eur J Haematol. 2008 Nov;81(5):391-8. doi: 10.1111/j.1600-0609.2008.01128.x. Epub 2008 Aug 6.

PMID:
18691257
12.

Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia.

Schmiegelow K.

Pediatr Hematol Oncol. 1991 Oct-Dec;8(4):301-12. Erratum in: Pediatr Hematol Oncol 1992 Apr-Jun;9(2):following 198.

PMID:
1782110
13.
14.

Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.

Keuzenkamp-Jansen CW, De Abreu RA, Blom HJ, Bökkerink JP, Trijbels JM.

Biochem Pharmacol. 1996 May 3;51(9):1165-71.

PMID:
8645339
15.

The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.

Clemmensen KK, Christensen RH, Shabaneh DN, Harila-Saari A, Heyman M, Jonsson OG, Wesenberg F, Rosthøj S, Schmiegelow K; Nordic Society of Pediatric Hematology, Oncology (NOPHO).

Pediatr Blood Cancer. 2014 Apr;61(4):653-8. doi: 10.1002/pbc.24867. Epub 2013 Nov 22.

PMID:
24265159
16.
17.

Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.

Toksvang LN, De Pietri S, Nielsen SN, Nersting J, Albertsen BK, Wehner PS, Rosthøj S, Lähteenmäki PM, Nilsson D, Nystad TA, Grell K, Frandsen TL, Schmiegelow K.

Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26519. Epub 2017 Apr 19. Erratum in: Pediatr Blood Cancer. 2018 Jan;65(1):.

PMID:
28423235
18.

Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.

Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K.

Acta Paediatr. 1998 Jan;87(1):108-11.

PMID:
9510461
19.

Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.

Zerra P, Bergsagel J, Keller FG, Lew G, Pauly M.

Pediatr Blood Cancer. 2016 Apr;63(4):712-5. doi: 10.1002/pbc.25841. Epub 2015 Nov 24.

PMID:
26878433
20.

Supplemental Content

Support Center